Drug intelligence / Profile preview

CS-1 CAR-T cells

Development stage: Unknown
Lead developer: Beijing Boren Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CS-1 CAR-T cells are an autologous, fully human chimeric antigen receptor (CAR) T-cell therapy targeting the CS-1 (also known as SLAMF7 or CD319) antigen. Developed by Beijing Boren Hospital, this therapy is primarily investigated for the treatment of relapsed and refractory multiple myeloma (RRMM). CS-1 is highly and nearly universally expressed on malignant plasma cells in multiple myeloma, making it a viable target, especially for patients who have failed or are ineligible for BCMA-targeted therapies. The fully human nature of the CAR construct is intended to reduce immunogenicity and potentially improve the persistence of the T cells in the patient's body.

Other names: SLAMF7 CAR-T cellsSLAMF-7 CAR-T cellsSLAMF 7 CAR-T cellsCD319 CAR-T cellsCD-319 CAR-T cellsCD 319 CAR-T cellsautologous fully human CS-1 CAR-T

Targets

BCMA (B-cell maturation antigen)SLAMF7 (Signaling lymphocytic activation molecule family member 7)

Beyond the preview

Go deeper on CS-1 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-1 CAR-T cells.

Explore the full profile